Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma
Cancer Medicine · 2025-03 · 14 (5)
DOI: 10.1002/cam4.70663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.03.2025. Verfasst von Camilla O Hoff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Neoplasm Recurrence, Local, Receptor, Notch1, Receptors, Notch. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Adenoid cystic carcinoma (ACC) with NOTCH‐activating mutations presents a clinical challenge due to its poor prognosis. NOTCH inhibitors have emerged as a potential therapy for ACC patients with NOTCH activation. This study aimed to evaluate the efficacy of NOTCH inhibitors in this patient population.
Methods
A retrospective analysis was conducted on patients with metastatic ACC harboring NOTCH pathway activation, who received NOTCH inhibitors at MD Anderson Cancer Center. NOTCH inhibitors included AL101, a gamma‐secretase inhibitor, and brontictuzumab, an antibody targeting NOTCH1. NOTCH pathway activation was assessed through genomic analysis for NOTCH‐activating mutations or immunohistochemistry for NOTCH1 intracellular domain (NICD1). Efficacy endpoints included best overall response (BOR) and progression‐free survival (PFS) per RECIST or MD Anderson bone response criteria.
Results
Twenty‐nine patients were included, with a predominance of solid histology (86%). NOTCH‐activating mutations were identified in 82% of patients, and 95% showed positive NICD1 staining. BOR revealed partial response in 17% of patients, stable disease in 55%, and progressive disease in 28%. Median response duration was longer for AL101 compared to brontictuzumab (9.9 vs. 1.7 months, p = 0.04). Median PFS with NOTCH inhibitor was 4.2 months (95% CI 2.7–8.6 months). Progression of nontarget lesions occurred in 34% of patients. Comparison with prior therapy showed longer PFS with NOTCH inhibitors (HR 0.38, 95% CI 0.19–0.78, p = 0.0065).
Conclusion
NOTCH inhibitors demonstrate activity in NOTCH‐activated ACC, surpassing the efficacy of observation or prior systemic therapies. However, limited PFS and progression of nontarget lesions suggest the potential need for combination therapy to address ACC heterogeneity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
- Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Stomatology, Discipline of Oral and Maxillofacial Pathology, School of Dentistry, University of Sao Paulo, Sao Paulo, Brazil.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Luana G de Sousa, Flavia Bonini, Yoshitsugu Mitani, Renata Ferrarotto
Förderung
- NCI NIH HHS
Zitieren
APA
Hoff, C. O., de Sousa, L. G., Bonini, F., Lago, E. D., Wang, K., Siqueira, J. M., Mitani, Y., El-Naggar, A. K., & Ferrarotto, R. (2025). Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. Cancer Medicine, 14(5). https://doi.org/10.1002/cam4.70663
Vancouver
Hoff CO, de Sousa LG, Bonini F, Lago ED, Wang K, Siqueira JM, et al. Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. Cancer Medicine. 2025;14(5). doi:10.1002/cam4.70663
BibTeX
@article{Hoff2025,
author = {Hoff, Camilla O and de Sousa, Luana G and Bonini, Flavia and Lago, Eduardo Dal and Wang, Kaiwen and Siqueira, Juliana M and Mitani, Yoshitsugu and El-Naggar, Adel K and Ferrarotto, Renata},
title = {Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {5},
doi = {10.1002/cam4.70663}
}
EUVIMED